Macrocyclic Complexes for Proteoglycan-Specific PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques, such as X-ray, MRI, and PET-CT, lack sensitivity and specificity for early diagnosis and monitoring of cartilage degenerative pathologies like osteoarthritis and chondrosarcoma, as they primarily provide indirect information on inflammation and bone alterations, failing to accurately target proteoglycans, which are key biomarkers for these conditions.
Innovation Solution
Development of macrocyclic complexes with quaternary ammonium groups attached to polyazamacrocycles, which form stable radiolabeled complexes with 64Cu, allowing for specific targeting and imaging of proteoglycans in PET imaging, thereby providing a more accurate and sensitive diagnostic tool for these pathologies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging techniques (X-ray, MRI, SPECT) are used, then structural or indirect metabolic information can be obtained, but sensitivity and specificity for early cartilage degeneration detection are insufficient
Solution Approach 1:
The patent changes the chemical parameters of the radiotracer by developing macrocyclic complexes with quaternary ammonium groups that specifically bind to proteoglycans. This chemical modification enables direct targeting of cartilage matrix components, dramatically improving detection sensitivity for early osteoarthritis changes before structural alterations occur.
Solution Approach 2:
The invention uses composite radiotracer molecules combining macrocyclic chelating agents with quaternary ammonium functional groups. This composite structure provides both stable 64Cu binding and specific electrostatic interaction with negatively charged proteoglycans, achieving high sensitivity without requiring complex imaging equipment.
2Measurement precision
If conventional radiotracers targeting bone remodeling are used, then bone metabolism can be visualized, but specific targeting of proteoglycans in cartilage is not achieved
Solution Approach 1:
The patent applies local quality by introducing quaternary ammonium groups at specific positions on the macrocyclic complex. These localized positive charges create specific electrostatic interactions with negatively charged sulfate and carboxyl groups on proteoglycans, enabling selective targeting of cartilage tissue while maintaining overall complex stability.
Solution Approach 2:
The macrocyclic complex acts as an intermediary molecule that bridges the radiocopper isotope and the proteoglycan target. The quaternary ammonium groups on this intermediary provide specific binding to proteoglycans, while the macrocyclic structure ensures stable complexation with 64Cu, solving both specificity and stability requirements.
3Measurement precision
If early diagnosis of osteoarthritis is pursued, then disease-modifying treatment opportunities arise, but current methods lack objective and sensitive evaluation criteria
Solution Approach 1:
The patent enables preliminary detection of osteoarthritis by targeting proteoglycan changes that occur before structural damage is visible on X-ray or MRI. The macrocyclic 64Cu complexes detect biochemical alterations in the cartilage matrix at the earliest stages, providing objective evaluation criteria for initiating disease-modifying treatments before irreversible damage occurs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The macrocyclic complexes ensure high uptake in target organs with low non-target uptake, offering improved sensitivity and specificity for proteoglycan-rich tissues, enabling early diagnosis and therapeutic follow-up of diseases associated with proteoglycan deregulation.
Implementation Method 1
the quaternary ammonium groups attached to polyazamacrocycles... form stable radiolabeled complexes... allowing for specific targeting and imaging of proteoglycans
Data Source
Figure 1~2
AI summary
The present invention concerns compounds of formula (I):their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.